| 000 | 01767 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250517053111.0 | ||
| 264 | 0 | _c20160916 | |
| 008 | 201609s 0 0 eng d | ||
| 022 | _a1423-0313 | ||
| 024 | 7 |
_a10.1159/000439136 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKoshibu, Kyoko | |
| 245 | 0 | 0 |
_aAlternative to LRRK2-IN-1 for Pharmacological Studies of Parkinson's Disease. _h[electronic resource] |
| 260 |
_bPharmacology _c2015 |
||
| 300 |
_a240-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aBenzodiazepinones _xadverse effects |
| 650 | 0 | 4 |
_aBlood-Brain Barrier _xdrug effects |
| 650 | 0 | 4 | _aCaco-2 Cells |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 |
_aDrug Discovery _xmethods |
| 650 | 0 | 4 | _aDrug Stability |
| 650 | 0 | 4 | _aHep G2 Cells |
| 650 | 0 | 4 |
_aHepatocytes _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLeucine-Rich Repeat Serine-Threonine Protein Kinase-2 |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMetabolic Clearance Rate |
| 650 | 0 | 4 |
_aMicrosomes, Liver _xdrug effects |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xadverse effects |
| 650 | 0 | 4 |
_aProtein Serine-Threonine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aPyrimidines _xadverse effects |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 | _aSubstrate Specificity |
| 650 | 0 | 4 | _aTissue Distribution |
| 700 | 1 | _avan Asperen, Judith | |
| 700 | 1 | _aGerets, Helga | |
| 700 | 1 | _aGarcia-Ladona, Javier | |
| 700 | 1 | _aLorthioir, Olivier | |
| 700 | 1 | _aCourade, Jean-Phillippe | |
| 773 | 0 |
_tPharmacology _gvol. 96 _gno. 5-6 _gp. 240-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1159/000439136 _zAvailable from publisher's website |
| 999 |
_c25272996 _d25272996 |
||